Design of phase 2 study of TAS-115, a novel oral multi-kinase inhibitor, in patients with idiopathic pulmonary fibrosis

BACKGROUND: TAS-115, a novel multi-kinase inhibitor, demonstrated antifibrotic effects in vitro and in vivo. METHODS: This is an open-label, intra-patient comparison, exploratory phase 2 study of TAS-115 to evaluate the efficacy and safety in idiopathic pulmonary fibrosis (IPF) patients when orally...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishioka, Yasuhiko, Homma, Sakae, Okubo, Takahito, Azuma, Arata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390536/
https://www.ncbi.nlm.nih.gov/pubmed/34471721
http://dx.doi.org/10.1016/j.conctc.2021.100832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390536/
https://www.ncbi.nlm.nih.gov/pubmed/34471721
http://dx.doi.org/10.1016/j.conctc.2021.100832

Ejemplares similares